Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Aspart (NovoLog) vs Insulin Lispro (Humalog)
An educational, source-based comparison of Insulin Aspart (NovoLog) and Insulin Lispro (Humalog) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with proline→aspartic acid at B28, reducing hexamer stability for rapid absorption and prandial glucose control.
- Prandial coverage
- CSII pump therapy
- Inpatient glycemic management
- • FDA-approved.
- • Hypoglycemia is the principal risk.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
Insulin Aspart (NovoLog) vs Insulin Lispro (Humalog) — Key differences
- Class: Insulin Aspart (NovoLog) is classified as Insulin Analog · Endocrine, while Insulin Lispro (Humalog) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Aspart (NovoLog) — prandial coverage; Insulin Lispro (Humalog) — prandial coverage in t1d/t2d.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.